Hamid S, Guillaumier S, Shah T, Arya M, Ahmed H U
Division of Surgery and Interventional Science. Urology Research Group, UCL. London. UK. Department of Urology. UCLH NHS Foundation Trust. London. UK.
Division of Surgery and Interventional Science. Urology Research Group, UCL. London. UK. Department of Urology. Whittington Hospital NHS Trust. London. UK.
Arch Esp Urol. 2016 Jul;69(6):375-83.
Focal therapy is a novel treatment option in localised prostate cancer with or without a visible lesion on MRI. Treatment for low to intermediate risk prostate cancer with focal therapy has demonstrated good short to medium term outcomes with fewer undesirable genitourinary side effects. This has made focal therapy more appealing to men who find the implications of radical treatment unacceptable or are unable to tolerate active surveillance. In this paper we review the literature for treatment options in prostate cancer recurrence post focal therapy. We also cover the different definitions of failure agreed upon in previous consensus meetings, as well as their implications on future management focal therapy patients.
聚焦治疗是局限性前列腺癌的一种新型治疗选择，无论MRI上有无可见病灶。采用聚焦治疗对低至中危前列腺癌进行治疗已显示出良好的短期至中期疗效，且泌尿生殖系统不良副作用较少。这使得聚焦治疗对那些认为根治性治疗的影响不可接受或无法耐受主动监测的男性更具吸引力。在本文中，我们回顾了聚焦治疗后前列腺癌复发的治疗选择的文献。我们还涵盖了先前共识会议中商定的不同失败定义，以及它们对聚焦治疗患者未来管理的影响。
